UC San Diego

UC San Diego Previously Published Works

Title

Visual Function Assessment in Simulated Real-Life Situations in HIV-Infected Subjects

Permalink https://escholarship.org/uc/item/3cx9t3bv

Journal PLOS ONE, 9(5)

ISSN

1932-6203

Authors

Barteselli, Giulio Chhablani, Jay Gomez, Maria Laura <u>et al.</u>

Publication Date

2014

DOI

10.1371/journal.pone.0097023

Peer reviewed

Visual Function Assessment in Simulated Real-Life Situations in HIV-Infected Subjects



Giulio Barteselli^{1,2¶}, Jay Chhablani^{1,3¶}, Maria Laura Gomez¹, Aubrey L. Doede¹, Laurie Dustin⁴, Igor Kozak^{1,5}, Dirk-Uwe Bartsch¹, Stanley P. Azen⁴, Scott L. Letendre⁶, William R. Freeman¹*

Department of Ophthalmology, Jacobs Retina Center at Shiley Eye Center, University of California San Diego, La Jolla, California, United States of America,
 Ophthalmological Unit, Department of Clinical Sciences and Community Health, Ca' Granda Foundation-Ospedale Maggiore Policlinico, University of Milan, Milan, Italy,
 Srimati Kanuri Santhamma Vitreo-Retina Service, L.V. Prasad Eye Institute, Hyderabad, India, 4 Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America, 5 King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia, 6 HIV Neurobehavioral Research Center, University of California San Diego, La Jolla, California, United States of America

Abstract

Visual function abnormalities are common in people living with HIV disease (PLWH) without retinitis, even after improvement in immune status. Abnormalities such as reduced contrast sensitivity, altered color vision, peripheral visual field loss, and electrophysiological changes are related to a combination of retinal dysfunctions, involving inner and outer retinal structures. The standard protocol for testing vision performance in clinical practice is the Early Treatment Diabetic Retinopathy Study (ETDRS) chart. However, this method poorly correlates with activities of daily living that require patients to assess visual stimuli in multiple light/contrast conditions, and with limited time. We utilized a novel interactive computer program (Central Vision Analyzer) to analyze vision performance in PLWH under a variety of light/contrast conditions that simulate stressful and real-world environments. The program tests vision in a time-dependent way that we believe better correlates with daily living activities than the non-timed ETDRS chart. We also aimed to correlate visual scores with retinal neuro-fiber layer thickness on optical coherence tomography. Here we show that visual acuity is more affected in PLWH in comparison to HIV-seronegative controls in varying contrast and luminance, especially if the nadir CD4+ T-cell count was lower than 100 cells/mm³. Visual impairment reflects the loss of retinal nerve fiber layer thickness especially of the temporalinferior sector. In PLWH the ETDRS chart test led to better visual acuity compared to the Central Vision Analyzer equivalent test, likely because patients had indefinite time to guess the letters. This study confirms and strengthens the finding that visual function is affected in PLWH even in absence of retinitis, since we found that the HIV serostatus is the best predictor of visual loss. The Central Vision Analyzer may be useful in the diagnosis of subclinical HIV-associated visual loss in multiple light/contrast conditions, and may offer better understanding of this entity called "neuroretinal disorder".

Citation: Barteselli G, Chhablani J, Gomez ML, Doede AL, Dustin L, et al. (2014) Visual Function Assessment in Simulated Real-Life Situations in HIV-Infected Subjects. PLoS ONE 9(5): e97023. doi:10.1371/journal.pone.0097023

Editor: Olaf Strauß, Eye Hospital, Charité, Germany

Received January 17, 2014; Accepted April 14, 2014; Published May 8, 2014

Copyright: © 2014 Barteselli et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This study was supported in part by National Institutes of Health (NIH) grants R01EY007366 and R01EY018589 (WRF), R01EY016323 (DUB), and an unrestricted fund from Research to Prevent Blindness to the Department of Ophthalmology, University of California San Diego. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: freeman@eyecenter.ucsd.edu

¶ These authors contributed equally as first authors.

Introduction

Visual function abnormalities are common in people living with human immunodeficiency virus (HIV) disease (PLWH) without retinitis, even after improvement in immune status with antiretroviral therapy (ART). [1,2] Abnormalities include reduced contrast sensitivity, altered color vision, peripheral visual field loss and electrophysiological changes.[3–9] These changes in visual function are thought to be caused by HIV-associated "neuroretinal disorder," which is characterized by damage in the retinal nerve fiber layer (RNFL), as detected by optical coherence tomography (OCT), most likely due to microinfarctions and microangiopathy. [10] Although the exact pathogenesis of HIVrelated microangiopathy remains uncertain, several hypotheses have been reported including direct HIV infection of vascular endothelial cells, damage from immune complexes, and rheological abnormalities. [11] Moreover, recent data from our group showed dysfunction of the outer retinal layers, especially photoreceptors and retinal pigment epithelium, in autopsy eyes of HIVseropositive donors. [12] Therefore, there may be a second separate mechanism of vision dysfunction in these eyes.

Since their introduction to clinical practice, the Snellen chart test and the more recent Early Treatment Diabetic Retinopathy Study (ETDRS) chart test have been the standard protocol for testing best-corrected visual acuity (BCVA). [13] However, these tests are unable to detect subtle visual loss, especially under low contrast or glare conditions. Indeed, it is generally recognized that the ETDRS chart test poorly correlates with activities of daily living [14] (such as driving at night or playing sports outside), since it's not time-dependent, and as it allows an evaluation of the BCVA only in a pre-determined single high-contrast glare environment. [15] If the widely used ETDRS chart test is poorly reliable in evaluating BCVA in other contrast or luminance conditions for normal eyes, this may be also worse for PLWH. Indeed, these patients have a poor low-contrast visual performance – even without any retinitis [2] – and can also have poor driving performance. [16,17] Thus, a method able to measure the visual function in varying contrast and glare conditions and in timedependent situations is needed.

The Central Vision Analyzer (CVA; Sinclair Technologies, LLC, Media, PA) is a new interactive computer program to analyze BCVA under conditions that simulate stressful and realworld environments. [18,19] This backlight-glare computer-based test for BCVA is able to simulate luminance, contrast, and glare conditions that one may experience in a variety of daily activities, such as glare, dim lighting, and night vision. Moreover, the CVA testing is a time-dependent technique, yielding a better assessment of real-life encounters. Therefore, it may be an ideal tool to assess visual function and to understand the visual behavior under reallife situations. The usefulness of this device has been tested in a registered study at http://clinicaltrials.gov (identification, NCT 02028351), but results are not yet published.

The present study of PLWH aims to 1) assess visual acuity measurements in simulated real-life situations using the CVA; 2) correlate visual scores with RNFL thickness on spectral-domain OCT; and 3) assess the best predictors of visual performance under different light/contrast conditions using the CVA.

Methods

Subjects

This prospective, cross-sectional study included 89 eyes of 47 PLWH without active or healed retinitis and 105 eyes of 57 HIVseronegative adults (Table 1). The PLWH were part of a cohort consecutively recruited from the University of California San Diego (UCSD) AIDS Ocular Research Unit at the Jacobs Retina Center in La Jolla, CA from June 2010 to June 2011. The PLWH were recruited during the annual visit scheduled for research purpose; none of the patients had any ocular symptoms at enrollment. The HIV-seronegative individuals were recruited from the local community. This study was approved by the UCSD Human Research Protections Program and followed the tenets of the Declaration of Helsinki. Signed informed consent was obtained from all subjects before enrollment.

PLWH were divided into two groups based on the nadir CD4+ T-cell count. The high-nadir CD4 group maintained CD4+ T-cell counts above 200 cells/mm³. From this group, 37 eyes from 19 persons were studied; 1 eye was excluded because of lens opacities. The low-nadir CD4 group included PLWH with nadir CD4+ Tcell counts lower than 200 cells/mm³ for at least 6 months in their medical history. In this group, 52 eyes from 28 patients were studied; 4 eyes were excluded because of a history of infectious retinitis. All PLWH were taking ART for at least 6 months prior to the time of the examination. The exclusion criteria included history of ocular opportunistic infections; visible ocular abnormalities on indirect ophthalmoscopy or slit-lamp ophthalmoscopy; intraocular pressure 22 mmHg or higher; spherical equivalent refractive error below -5 diopters or above +2.5 diopters; and concurrent disease that could cause retinal damage, such as diabetes or glaucoma. In the HIV-seronegative control group, 105 eyes from 57 volunteers were studied; 3 eyes were excluded because of significant lens opacities; 6 eyes were excluded because of macular pathology affecting vision.

Ocular Examination and Central Vision Analyzer Testing

All patients had a complete ocular examination, including BCVA examination using standard ETDRS charts, slit-lamp examination, intraocular pressure measurement, indirect ophthalmoscopy under dilated pupils, and peripapillary RNFL thickness measurement on Heidelberg Spectralis (Heidelberg Engineering, Carlsbad, CA).

Before dilation, patients underwent CVA testing using a Landolt C presentation of 900 msec in 6 different light/contrast conditions (Table 1). The Landolt C appeared in three mesopic conditions of 99% contrast against 3 Cd/m2 background ("M1" module, that is full-contrast module of white letters presented on a black background), followed by lower contrast modules of 64% contrast ("M2" module, simulating an environment similar to a dimly lit restaurant) and 43% contrast ("M3" module, simulating an environment similar to driving at dusk). Photopic glare (backlighting) conditions were simulated using 99% contrast against a 200 Cd/m2 background ("G1" module, that is a full-contrast module of black letters presented on a bright background), 10% contrast ("G2" module, simulating an environment similar to playing a sport outside with the sun over head), and 8% contrast ("G3" module, simulating an environment similar to playing a sport outside with the sun 15 degrees off-axis). The CVA displayed a tumbled Landolt C in 4 different directions on a monitor positioned 4 meters from the patient, and to which the person responds by pressing one of 4 buttons on a keypad (corresponding to the 4 different orientations). The program utilized a 0.05 logMAR staircase of optotype size and thresholds for the smallest Landolt C for which the person accurately identifies the tumbled position twice with 2 inaccurate responses at the next smaller size. At the end of the test, results were automatically presented to the examiner in a report as six separate BCVA scores in logMAR units for each of the simulated light/contrast conditions. [10].

Table 1	1. (⁻ haracteristics	of each	of the	CVA	modules	tested
IMMICI					~ * / `	modules	

CVA modules	Contrast (MC)	Landolt C Luminance	Background luminance	Simulated Environment
Mesopic 1 (M1)	99%	220 Cd/m ²	3 Cd/m ²	Full contrast
Mesopic 2 (M2)	64%	4.8 Cd/m ²	3 Cd/m ²	Dim restaurant
Mesopic 3 (M3)	43%	8.4 Cd/m ²	3 Cd/m ²	Driving at dusk
Glare 1 (G1)	99%	1.6 Cd/m ²	200 Cd/m ²	Full contrast
Glare 2 (G2)	10%	180 Cd/m ²	200 Cd/m ²	Outside with sun over head
Glare 3 (G3)	8%	186 Cd/m ²	200 Cd/m ²	Outside with sun 15 $^\circ$ off-axis

CVA, Central Vision Analyzer; MC, Michelson Contrast; Cd/m², Candelas per Meter Squared. doi:10.1371/journal.pone.0097023.t001

Statistical Analysis

Mean age and duration of HIV were compared between HIV groups using independent samples t-tests and chi-square tests were used to test for gender differences between groups. Generalized Estimating Equations (GEE) were used to compare LogMAR BCVA and RNFL measures between HIV groups, adjusting for gender. Bonferonni adjustments were made for multiple pairwise comparisons. GEE was also used for the gender-adjusted univariate and multivariate analyses, testing for the independent association of HIV status and RNFL with logMAR BCVA. Statistical analyses were performed using SAS statistical software version 9.3 (SAS Inc, Cary, North Carolina, USA). A p-value < 0.05 was considered to be statistically significant.

Results

Demographic and Disease Characteristics

At the time of examination, all 47 PLWH showed near-normal immune status with ART. The mean CD4+ T-cell count was 672 ± 281 cells/mm³ (range, 264–1,305 cells/mm³) and the mean HIV plasma viral load was 24.9 ± 19.9 copies/mL (range, 0–50 copies/mL). Table 2 presents groups demographics. The two HIV groups (i.e., low-nadir CD4 group and high-nadir CD4 group) were similar for age (p = 0.66), as were the HIV-seropositive and HIV-seronegative groups (p = 0.45). The HIV-seropositive group included more men than women compared to the HIV-seronegative group (p = 0.03). The duration of HIV disease was similar between the two HIV groups (p = 0.62).

Assessment of Visual Acuity Measurements using the Central Vision Analyzer

Comparing visual acuity measurements for various mesopic and backlight-glare conditions among the 3 groups (Table 3), we found statistically significant differences for ETDRS (p = 0.029), M1 (p <0.001), M2 (p = 0.021) and M3 (p = 0.029), and G1 modules (p = 0.001), after adjusting for gender. In particular, the high-nadir CD4 group experienced worse visual scores than HIV-seronegative subjects for ETDRS (p = 0.028) and G1 scores (p < 0.001). The low-nadir CD4 group experienced worse visual scores than HIVseronegative subjects for ETDRS (p = 0.058), M1 (p = 0.001), M2 (p = 0.012) and M3 (p = 0.021), and G1 modules (p < 0.001). The acuity drop between ETDRS and G1 was also significantly different between groups (p = 0.005); in particular, it was greater in the low-nadir CD4 group than in HIV-seronegative subjects (p = 0.001). Among PLWH, the two groups had similar BCVA scores (p>0.05). Gender-adjusted Spearman correlation coefficients with visual scores among PLWH showed that G1 scores were correlated with vision decrease (p < 0.001), while EDTRS scores were not (p = 0.100). No significant correlation was found between presumed duration of HIV and visual scores in any CVA module.

In addition, we explored the hypothesis that the vision dysfunction has a common pathway to neurophysiological dysfunction. Changing the definition of low-nadir CD4 value from 200 to 100 cells/mm³, statistical analysis showed more robust results (data not shown); the high-nadir CD4 group (over 100 cells/mm³) experienced worse visual scores than HIV-seronegative subjects not only for ETDRS (p = 0.039) and G1 scores (p < 0.003) as we described above, but also for M1 (p = 0.001), M2 (p = 0.014) and M3 (p = 0.020).

Variable	Low CD4*	High CD4	p-value	HIV+	-VIH	p-value	Total
No. of subjects	28	19		47	57		104
No. of eyes	52	37		89	105		194
Mean age (y)	55.1	53.9	0.66 ^T	54.6	56.2	0.45 ^T	55.5
Age range (y)	41–85	44–73		41–85	28-84		28-85
Men (%)	79%	100%	0.03 ^C	87%	68%	0.03 ^C	77%
Women (%)	21%	0%0		13%	32%		23%
Duration of HIV (y)	18.2	17.0	0.62 ^T	17.7	n/a		n/a
Y, years; n/a, not applicable; *CD4+ T-cell counts lower than 200 cells/mm3 for at least ϵ T = Independent samples t-test; C = Chi-square test. doi:10.1371/journal.pone.0097023.t002	6 months in their medical history.						

2. Demographics of Study Participants

Table

	HIV- (57)	HIV+ (47)			HIV – vs high CD4	HIV- vs low CD4	High vs low CD4
CVA (logMAR)		low CD4 (28)	high CD4 (19)	p-value*	p-value*	p-value*	p-value*
-DRS Lsmear	0.067	- 0.008	-0.015	0.029	0.028	0.058	0.843
SE	0.013	0.029	0.019				
1 Lsmear	n — 0.043	0.140	0.129	<0.001	<0.001	0.001	0.863
SE	0.02	0.045	0.046				
2 Lsmear	٥.194 ر	0.334	0.309	0.021	0.078	0.012	0.736
SE	0.030	0.048	0.057				
3 Lsmear	٥.313 م	0.462	0.434	0.029	0.070	0.021	0.726
SE	0.033	0.057	0.057				
1 Lsmear	0.018	0.191	0.102	0.001	0.161	<0.001	0.195
SE	0.026	0.042	0.053				
2 Lsmear	٥.354 م	0.429	0.399	0.421	0.444	0.240	0.699
SE	0.028	0.059	0.049				
3 Lsmear	0.446	0.546	0.456	0.362	0.885	0.158	0.291
SE	0.035	0.063	0.055				
"DRS - G1 Lsmear	n —0.085	-0.199	-0.118	0.005	0.528	0.001	0.134
SE	0.023	0.027	0.046				

positive patients, adjusted for gender 2 י אוח פייי -+i,-o +00 T-LIA 2 Analycic of visual actitiv After correcting for gender (Table 4), the global peripapillary RNFL thickness ("G" value on the Heidelberg Spectralis) was similar between groups (p = 0.353). The only RNFL sector that showed difference between groups was the nasal-superior (p = 0.039); the low-nadir CD4 group had thinner RNFL compared the high-nadir CD4 group (p = 0.021) as well as compared to HIV-seronegative subjects (p = 0.041). No correlation was noted between duration of HIV disease and RNFL thickness.

Changing the definition of low-nadir CD4 value from 200 to 100 cells/mm³, statistical analysis showed more robust results (data not shown); the global peripapillary RNFL thickness turned out to be significantly different between groups (p = 0.032), and in particular it was thinner in the low-nadir CD4 group compared to HIV-seronegative subjects (p = 0.011).

Assessment of the Best Predictors of Visual Performance

Gender-adjusted univariate regression analysis (Table 5) confirmed that the HIV serostatus was highly associated with visual scores for M1 (p<0.001), M2 (p=0.006), M3 (p=0.008), and G1 (p<0.001), as well as for ETDRS (p=0.012). The global RNFL thickness was associated with visual scores for M1 (p=0.040), M2 (p=0.018), and M3 (p=0.005). The temporal-inferior RNFL sector was the most associated to the vision performance: thinning of temporal-inferior RNFL sector was associated to visual scores for M1 (p=0.033) and M2 modules (p=0.016). A trend of association was found between thinning of temporal-inferior RNFL sector and visual scores for M3 (p=0.064) and for ETDRS (p=0.065).

Gender-adjusted multivariate regression analysis (Table 5) showed that HIV serostatus was the best predictor of visual performance under different light/contrast conditions and correlated well with ETDRS (p = 0.012), M1 (p < 0.001), M2 (p = 0.031), M3 (p = 0.029), and G1 modules (p = 0.007). Thickness of the temporal-inferior RNFL sector was also an independent predictor of visual performance, especially for M1 (p = 0.033) and M2 modules (p = 0.032).

Discussion

This study documented visual function abnormalities and RNFL damage in PLWH without retinitis and confirmed findings of other studies. PLWH have been reported to present reduced contrast sensitivity, altered color vision, peripheral visual field loss and electrophysiological changes [3–9]. In our study, the visual function of HIV-seropositive and HIV-seronegative patients was comprehensively analyzed in several contrast and luminance conditions using a unique device – the Central Vision Analyzer – that has been already approved by the Food And Drug Administration. This new interactive computer program measures logMAR visual acuity under conditions that simulate stressful and real-world environments [18].

We demonstrated that visual scores are worse in PLWH in comparison to HIV-seronegative subjects in most of the CVA light/contrast conditions, especially if patients had history of nadir CD4+ T-cell count lower than 100 cells/mm³. The HIV serostatus turned out to be the best independent predictor of visual performance under different light/contrast conditions. We have already demonstrated that visual scores decline with decreasing contrast and luminance conditions both in healthy eyes and in eyes with macular pathology (Gomez ML, et al. IOVS 2011,52;ARVO E-Abstract 5555). Moreover, in that study we found that the drop in visual scores with decreasing light and contrast does not differ between these two groups, even if the visual outcome is worse for patients with macular pathology. In eyes with age-related macular degeneration, damage of the outer retinal layers is the principal cause of low visual outcomes. [20] In eyes of PLWH, visual disturbances are mainly related to damage of the inner retinal layers such as the RNFL, as detected by OCT, most likely due to microinfarctions and microangiopathy. [10] In addition, recent evidence has demonstrated a significant dysfunction of the outer retinal layers in autopsy eyes of HIV-seropositive donors even in the absence of infection or clinically apparent retinal lesions. [12] Therefore we can conclude that the lower visual outcomes in eyes of PLWH compared to HIV-seronegative controls may be related to a combination of retinal dysfunctions, involving both inner and outer retinal structures.

The luminance and contrast of the G1 module is the most similar to that of the ETDRS chart test; however in PLWH we found that the ETDRS chart test led to better visual acuity compared to the G1 test. This finding is likely due to the timedependent nature of the automated CVA testing. Since the EDTRS chart is not time-dependent, patients have indefinite time to visualize letters on the chart; however this approach does not mimic real-world situations. The CVA testing simulates stressful and real-world environments, recreating light and contrast conditions of time-dependent real life activities such as reading, driving, or recognizing objects that are presented transiently. Therefore, if letters are projected only for a short period of time, patients with macular pathology may fail to recognize them since they have slower reading speed than healthy patients. [21] Similarly, PLWH may not be able to speedily recognize letters because of HIV-related cognitive impairment, which is common and can affect psychomotor speed and executive function. [22].

Although the nadir CD4+ T-cell count reflects the past severity of the immune disease, in our study we did not find significantly reduced visual scores in the low-nadir CD4 group compared to the high-nadir CD4 group in any of the several light and contrast conditions. Interestingly, the visual drop in high-contrast environments (i.e. ETDRS and G1) was also similar between HIVseropositive groups. Previous reports have described abnormalities on visual field and multifocal electroretinogram (mfERG) in eyes of PLWH in the absence of infectious retinitis; patients with reduced immune status differed more from healthy eyes than eyes from patients who never were observed to have reduced immune status. [8,23] However, a subsequent study using more powerful data analysis showed equal severity of b-latency abnormalities on mfERG in the low- and high-CD4 groups. [24] The similarity of mfERG abnormalities in the low- and high-nadir CD4 groups [24], as well as the similar visual loss detected by the CVA as described in the present study, indicates that good immune status during ART may not protect against retinal damage. However, we also can hypothesize that the immune status as indicated by the nadir CD4+ T-cell count may not be the best predictor of visual dysfunctions in HIV-positive subjects. Many other factors may be implicated, such as current and highest HIV RNA level, duration of HIV RNA suppression over time, number of opportunistic infections, neurocognitive function, and also distribution of ART drugs into the central nervous system. [25] Although we know the date of diagnosis of HIV seropositivity, some patients on presentation already had HIV for many years. This may explain why we did not find correlations between duration of HIV seropositivity and visual scores or RNFL thickness. A more important predictor of visual performance and retinal damage may be knowledge of the duration of low CD4+ T-cell counts and uncontrolled HIV RNA. Such data is extremely difficult to procure. Although we have some of these data on a small number

MCI (in) MC - (x) MC - (x)				HIV+ (47)			HIV- vs bich CD4	HIV- vs low CD4	High vs low CD4
NHL incode (3b) bigh CD4 (3b) bigh CD4 (3b) bydue* brune*			HIV (57)						
"Gridobul Lsmean 946 910 927 0.333 0.604 0.155 0.663 fr 13 21 33 0.013 0.015 0.053 0.063 frep 13 21 33 0.187 0.030 0.701 frep 14 29 28 0.187 0.843 0.309 0.701 frep-5up 135 185 123.0 0.643 0.701 0.701 frep-5up 53 183 123.0 0.643 0.701 0.701 frep-5up 53 183 123.0 0.643 0.701 0.701 frep-5up 55 1002 0.701 0.701 0.701 0.701 frep-14 1037 0.72 0.702 0.701 0.701 0.701 frep-15 1037 0.702 0.703 0.701 0.701 0.701 frep-16 1037 0.702 0.702 0.701 0.702	RNFL (µm)			low CD4 (28)	high CD4 (19)	p-value*	p-value*	p-value*	p-value*
(4) (1) <td>"G" (global)</td> <td>Lsmean</td> <td>94.6</td> <td>91.0</td> <td>92.7</td> <td>0.353</td> <td>0.604</td> <td>0.155</td> <td>0.663</td>	"G" (global)	Lsmean	94.6	91.0	92.7	0.353	0.604	0.155	0.663
TenpLinear 67 67 64 0.187 0.05 0.20 0.20 0.07 F 16 29 28 2 2 28 28 28 26 266 $Tenp-Lup$ 133 133 133 0.641 0.359 0.560 0.560 $Tenp-Lup$ 157 958 1092 0.641 0.641 0.641 0.641 $Na-Sup$ 1057 958 1092 0.639 0.641 0.641 0.641 $Na-Sup$ 107 22 23 4.2 0.497 0.237 0.641 0.643 $Na-Int1071071070.610.220.610.610.61Na-Int113710749800.010.020.7260.439Na-Int113710749800.010.020.7260.439Na-Int113710749800.010.020.3170.207Na-Int1137107410800.640.640.760.76Na-Int1132126212870.640.6240.780.726Na-Int1132126212870.760.780.78Na-Int1132126212870.780.780.78Na-Int1128712870.780.780.790.79Na-Int11282128$		SE	1.3	2.1	3.3				
6E 16 29 28 Temp-Sup Linear 1235 1185 1230 0569 0560 Temp-Sup E 32 44 61 0.359 0560 0560 Kend 1057 958 1092 0.645 0.649 0.641 0.560 0560 Nas-Sup Linear 1057 958 1092 0.039 0.530 0.041 0.50 Nas-Sup Linear 707 222 76.3 0.497 0.237 0.247 0.43 Nas-Inf Emer 707 72.3 0.497 0.237 0.726 0.439 Nas-Inf Linear 1137 1074 980 0.071 0.029 0.337 0.237 0.237 Nas-Inf Linear 1132 1074 980 0.249 0.249 0.249 0.249 0.249 Nas-Inf Linear 1132 1074 902 0.249 0.249 0.249 0.249 </td <td>Temp</td> <td>Lsmean</td> <td>69.7</td> <td>65.7</td> <td>64.2</td> <td>0.187</td> <td>0.095</td> <td>0.230</td> <td>0.707</td>	Temp	Lsmean	69.7	65.7	64.2	0.187	0.095	0.230	0.707
Temp-Sup Lismet 118.5 123.0 16.45 0.941 0.359 0.560 SE 3.2 4.4 6.1 0.53 0.54 0.560 Ma-Sup Linnen 105.7 95.8 109.2 0.633 0.647 0.641 0.641 Ma-Sup Linnen 70.7 95.8 109.2 0.6497 0.647 0.641 0.641 0.641 0.643 Ma-Linnen Linnen 70.7 76.3 0.497 0.237 0.766 0.439 0.643 Ma-Linnen Linnen 70.7 76.3 0.761 0.766 0.439 0.766 0.439 Ma-Linnen Linnen 107 0.237 0.726 0.737 0.737 Ma-Linnen Linnen 107 0.0497 0.022 0.769 0.707 Ma-Linnen Linnen 107 0.021 0.021 0.769 0.707 Ma-Linnen Linnen 126.2 128.7		SE	1.6	2.9	2.8				
F 32 44 61 $Na-Sup$ $Imea$ 1057 958 002 0021 0021 $Na-Sup$ $Imea$ 1057 958 1092 0.039 0.530 0.041 0.021 Na $Imea$ 707 722 763 0.497 0.237 0.043 Na 707 722 763 0.497 0.237 0.439 $Na-Int$ 707 722 763 0.237 0.376 0.439 $Na-Int$ 1137 1074 980 0.071 0.022 0.337 0.237 $Na-Int$ $Imea$ 1137 1074 980 0.071 0.022 0.337 0.207 $Na-Int$ $Imea$ 1132 1262 1287 0.249 0.37 0.237 $Na-Int$ $Imea$ 1002 0.240 0.037 0.237 0.237 0.237 $Na-Int$	Temp-Sup	Lsmean	123.5	118.5	123.0	0.645	0.941	0.359	0.560
Na-Sup Lsmen 1057 958 1092 0.039 0.530 0.041 0.021 SE 3.2 3.7 3.7 4.3 4.3 0.031 0.041 0.031 0.031 As Lsmen 707 7.2 7.3 0.497 0.237 0.736 0.439 Na-Hd Lsmen 707 7.2 7.4 0.237 0.736 0.439 Na-Hd Lsmen 113.7 1074 980 0.071 0.022 0.337 0.237 0.237 Na-Hd Lsmen 113.7 1074 0.021 0.021 0.337 0.237 0.237 Na-Hd Lsmen 122 126.7 128.7 0.406 0.64 0.337 0.207 Semi-Hd 132 1262 128.7 0.406 0.624 0.726 0.707 Semi-Hd 132 1262 128.7 0.406 0.649 0.780 0.727 Semi-Hd		SE	3.2	4.4	6.1				
SE 3.2 3.7 4.3 Nas Linear 70.7 7.2 4.3 Nas Linear 70.7 7.2 7.6.3 0.497 0.726 0.439 Nas-Inf Linear 11.3.7 107.4 98.0 0.071 0.022 0.337 0.207 Nas-Inf Linear 11.3.7 107.4 98.0 0.071 0.022 0.337 0.207 Nas-Inf Linear 11.3.7 107.4 0.071 0.022 0.337 0.207 Nas-Inf Linear 11.3.7 107.4 0.0406 0.624 0.701 0.207 Nas-Inf Linear 13.2 126.2 128.7 0.406 0.624 0.712 Sf 2.9 3.2 6.4 0.524 0.722 0.722	Nas-Sup	Lsmean	105.7	95.8	109.2	0.039	0.530	0.041	0.021
Mas Lsmen 707 722 763 0.497 0.237 0.726 0.439 SE 2.2 3.5 4.2 0.436 0.439 Na-Inf Lsmen 113.7 107.4 980 0.071 0.022 0.337 0.207 Na-Inf Lsmen 13.7 5.2 5.5 0.020 0.071 0.023 0.207 0.207 TemP-Inf Lsmen 13.2 126.2 128.7 0.406 0.624 0.180 0.722 TemP-Inf Lsmen 13.2 126.2 128.7 0.406 0.624 0.730 0.722 SF 2.9 3.2 6.4 128.7 0.406 0.549 0.722		SE	3.2	3.7	4.3				
SE 2.2 3.5 4.2 Na-hf Lsmein 1137 1074 98.0 0.071 0.022 0.337 0.207 Na-hf Lsmein 1137 1074 98.0 0.071 0.022 0.337 0.207 Temp-hf Lsmein 1322 126.2 128.7 0.406 0.624 0.180 0.722 Femp-hf Lsmein 132 126.2 128.7 0.406 0.624 0.180 0.722	Nas	Lsmean	70.7	72.2	76.3	0.497	0.237	0.726	0.439
Mas-Inf Lsmean 113.7 107.4 98.0 0.071 0.022 0.337 0.207 SE 3.7 5.2 5.5		SE	2.2	3.5	4.2				
SE 3.7 5.2 5.5 Temp-Inf Lsmean 13.2 126.2 128.7 0.406 0.624 0.180 0.722 F 2.9 3.2 6.4 6.4 0.52 0.722	Nas-Inf	Lsmean	113.7	107.4	98.0	0.071	0.022	0.337	0.207
Temp-Inf Lsmean 132.2 126.2 128.7 0.406 0.624 0.180 0.722 SF 2.9 3.2 6.4 6.4 0.130 0.722		SE	3.7	5.2	5.5				
SE 2.9 3.2 6.4	Temp-Inf	Lsmean	132.2	126.2	128.7	0.406	0.624	0.180	0.722
		SE	2.9	3.2	6.4				

, . : / 111/ - Table 5. Regression analyses of HIV status (seronegative vs seropositive) and retinal nerve fiber layers thickness with visual acuity, adjusted for gender.

		Univariate		Multivariate	
BCVA (logMAR)	RNFL	HIV status	RNFL	HIV status	RNFL
		p-value*	p-value*	p-value*	p-value*
M1	"G" (global)	<0.001	0.040	<0.001	0.055
	Temp-Inf	<0.001	0.033	<0.001	0.033
M2	"G" (global)	0.006	0.018	0.031	0.037
	Temp-Inf	0.006	0.016	0.023	0.032
	Temp-Sup	0.006	0.123	0.017	0.130
M3	"G" (global)	0.008	0.005	0.029	0.010
	Temp-Inf	0.008	0.064	0.019	0.098
	Nasal-Sup	0.008	0.076	0.021	0.117
G1	"G" (global)	<0.001	0.047	0.007	0.058
	Nasal-Sup	<0.001	0.057	0.006	0.074
ETDRS	"G" (global)	0.012	0.016	0.012	0.268
	Temp-Inf	0.012	0.065	0.010	0.081

*Applying Generalized Estimating Equations (GEE); BCVA, best corrected visual acuity; RNFL, retinal nerve fiber layer; ETDRS, Early Treatment Diabetic Retinopathy Study; M1, full-contrast module of white letters presented on a black background; M2, 64% contrast module simulating an environment similar to a dimly lit restaurant; M3, 43% contrast module simulating an environment similar to driving at dusk; G1, full-contrast module of black letters presented on a bright background. doi:10.1371/journal.pone.0097023.t005

of our patients at the moment, we do not have sufficient data for our analysis. Therefore, in this pilot analysis, we included all patients and classified them based on the limited data currently available.

We also found thinning of the global peripapillary RNFL in the low-nadir CD4 group compared to HIV-seronegative subjects, as well as association between global RNFL and visual scores for most CVA modules. Regression analysis indicated that the temporal-inferior RNFL sector was the most associated sector with visual performance in PLWH. This is consistent with previous studies: a strong relationship was found between contrast sensitivity and color vision with peripapillary RNFL in PLWH, most apparent in the temporal quadrant. [26] These results are biologically plausible; BCVA, contrast sensitivity, and color vision are macular functions, and it is not surprising that correlations were found primarily in the temporal RNFL, which reflects the papillo-macular bundle. Because clinically we see a similar distribution of cotton-wool spots in HIV-seropositive patients with low-CD4 counts, we assume that these retinal microinfarctions are at least one factor responsible for subsequent defects in RNFL thickness. Indeed, histopathologic and tomographic studies showed significance of cotton-wool spots in pathogenesis of retinal neural tissue loss. [27,28].

There are a number of limitations to this study. Sample sizes were relatively small, which may have affected our ability to identify some potential associations. Certain components of study participants' medical history was self-reported and approximate, such as date of HIV seroconversion, total number of opportunistic infections, and ART duration and type over time. A comprehensive analysis of ART is not possible in our population and might prove extremely difficult because ART protocols are changed frequently; longitudinal studies are necessary to assess the effect of ART drugs on visual function. In addition, knowing the changes in HIV RNA level overtime would be useful for further analysis. Unfortunately, because of the long duration of HIV infection in our study population (average duration: 17 years) and because of the relatively recent referral to our center, we do not have precise data on fluctuations of the HIV RNA level in our population. This should be a topic of future studies. However, we found strong and consistent results and we believe that it is unlikely that they would be observed based on study deficiencies as opposed to real effects.

In conclusion, in our study we analyzed the visual function in PLWH without active retinitis using a novel interactive computer program that is able to test visual acuity in a variety of real-life mesopic and glare conditions. We demonstrated that the HIV status (positive vs negative) is the best independent predictor of visual performance under different light/contrast conditions. Visual function is more affected in PLWH in comparison to HIV-seronegative subjects in varying contrast and luminance, especially if patients had history of nadir CD4+ T-cell count lower than 100 cells/mm³, and reflects the loss of RNFL thickness especially of the temporal-inferior sector. This study confirms, strengthens, and implements the previous finding that visual function is affected in PLWH even in absence of retinitis. We suggest paying particular attention while evaluating PLWH, even if the immune system is near-normal at the time of examination, because they may experience a greater visual dysfunction than expected. The CVA, or a similar time-dependent vision testing, may be of clinical use in the non-invasive diagnosis of early subclinical HIV-associated visual dysfunction, and may offer better understanding of this entity called "neuroretinal disorder".

Author Contributions

Conceived and designed the experiments: GB JC MLG WRF. Performed the experiments: ALD GB. Analyzed the data: LD SPA. Contributed reagents/materials/analysis tools: MLG DUB IK. Wrote the paper: GB JC SLL WRF.

References

- Freeman WR, Van Natta ML, Jabs D, Sample PA, Sadun AA, et al (2008) Vision function in HIV-infected individuals without retinitis: report of the Studies of Ocular Complications of AIDS Research Group. Am J Ophthalmol 145: 453–462.
- Mueller AJ, Plummer DJ, Dua R, Taskintuna I, Sample PA, et al. (1997) Analysis of visual dysfunctions in HIV-positive patients without retinitis. Am J Ophthalmol 124: 158–67.
- Mutlukan E, Dhillon B, Aspinall P, Cullen JF (1992) Low contrast visual acuity changes in human immuno-deficiency virus (HIV) infection. Eye (Lond) 6: 39– 42.
- Quiceno JI, Capparelli E, Sadun AA, Munguia D, Grant I, et al (1992) Visual dysfunction without retinitis in patients with acquired immunodeficiency syndrome. Am J Ophthalmol 113: 8–13.
- Shah KH, Holland GN, Yu F, Van Natta M, Nusinowitz S, Studies of Ocular Complications of ARG (2006) Contrast sensitivity and color vision in HIVinfected individuals without infectious retinopathy. Am J Ophthalmol 142: 284– 292.
- Sommerhalder J, Baglivo E, Barbey C, Hirschel B, Roth A, et al (1998) Colour vision in AIDS patients without HIV retinopathy. Vision Res 38: 3441–3446.
- Falkenstein I, Kozak I, Kayikcioglu O, Cheng L, Bartsch DU, et al (2006) Assessment of retinal function in patients with HIV without infectious retinitis by multifocal electroretinogram and automated perimetry. Retina 26: 928–934.
- Kozak I, Sample PA, Hao J, Freeman WR, Weinreb RN, et al (2007) Machine learning classifiers detect subtle field defects in eyes of HIV individuals. Trans Am Ophthalmol Soc 105: 111–118.
- Sample PA, Plummer DJ, Mueller AJ, Matsubara KI, Sadun A, et al (1999) Pattern of early visual field loss in HIV-infected patients. Arch Ophthalmol 117: 755–760.
- Kozak I, Bartsch DU, Cheng L, Kosobucki BR, Freeman WR (2005) Objective analysis of retinal damage in HIV-positive patients in the HAART era using OCT. Am J Ophthalmol 139: 295–301.
- Geier SA, Hammel G, Bogner JR, Kronawitter U, Berninger T, et al (1994) HIV-related ocular microangiopathic syndrome and color contrast sensitivity. Invest Ophthalmol Vis Sci 35: 3011–3021.
- Kozak I, Sasik R, Freeman WR, Sprague IJ, Gomez ML, et al (2013) A Degenerative Retinal Process in HIV-Associated Non-Infectious Retinopathy. PloS one 8: e74712.
- Lim LA, Frost NA, Powell RJ, Hewson P (2010) Comparison of the ETDRS logMAR, 'compact reduced logMar' and Snellen charts in routine clinical practice. Eye (Lond) 24: 673–677.
- Pesudovs K, Hazel CA, Doran RM, Elliott DB (2004) The usefulness of Vistech and FACT contrast sensitivity charts for cataract and refractive surgery outcomes research. Br J Ophthalmol 88: 11–16.
- Yavuz GA, Unver YB, Bekiroglu N, Presti P, Sinclair SH (2009) Central field perimetry of discriminated targets: I. Results for normal individuals using highcontrast targets. Eye (Lond) 23: 2082–2089.

- Cheng S KH, Bartsch DU, Kozak I, Marcotte TD, Freeman WR (2011) Relationship between retinal nerve fiber layer thickness and driving ability in patients with human immunodeficiency virus infection. Graefes Arch Clin Exp Ophthalmol 249: 1643–1647.
- Holland GN, Kappel PJ, Van Natta ML, Palella FJ, Lyon AT, et al (2010) Association between abnormal contrast sensitivity and mortality among people with acquired immunodeficiency syndrome. Am J Ophthalmol 149: 807–816.
- Gutstein W, Sinclair SH, North RV, Bekiroglu N (2010) Screening athletes with Down syndrome for ocular disease. Optometry 81: 94–99.
- Gomez ML (2014) Measuring the Quality of vision after cataract surgery. In "Cataract surgery and lens implantation". Curr Opin Ophthalmol 25: 3–11.
- El-Emam S, Chhablani J, Barteselli G, Wang H, Lee SN, et al (2013) Correlation of Spectral Domain Optical Coherence Tomography Characteristics with Visual Acuity in Eyes with Subfoveal Scarring after Treatment for Wet Age-Related Macular Degeneration. Retina 33: 1249–1257.
- Nguyen NX, Weismann M, Trauzettel-Klosinski S (2009) Improvement of reading speed after providing of low vision aids in patients with age-related macular degeneration. Acta Ophthalmol 87: 849–853.
- Manly JJ, Smith C, Crystal HA, Richardson J, Golub ET, et al (2011) Relationship of ethnicity, age, education, and reading level to speed and executive function among HIV+ and HIV- women: the Women's Interagency HIV Study (WIHS) Neurocognitive Substudy. J Clin Exp Neuropsychol 33: 853–863.
- Falkenstein IA, Bartsch DU, Azen SP, Dustin L, Sadun AA, et al (2008) Multifocal electroretinography in HIV-positive patients without infectious retinitis. Am J Ophthalmol 146: 579–588.
- Goldbaum MH, Falkenstein I, Kozak I, Hao J, Bartsch DU, et al (2008) Analysis with support vector machine shows HIV-positive subjects without infectious retinitis have mfERG deficiencies compared to normal eyes. Trans Am Ophthalmol Soc 106: 196–204.
- Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, et al (2008) Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 65: 65–70.
- Kalyani PS, Holland GN, Fawzi AA, Arantes TE, Yu F, et al (2012) Association between retinal nerve fiber layer thickness and abnormalities of vision in people with human immunodeficiency virus infection. Am J Ophthalmol 153: 734–742, 742 e1.
- Tenhula WN, Xu SZ, Madigan MC, Heller K, Freeman WR, Sadun AA (1992) Morphometric comparisons of optic nerve axon loss in acquired immunodeficiency syndrome. Am J Ophthalmol 113: 14–20.
- Gomez ML, Mojana F, Bartsch DU, Freeman WR (2009) Imaging of long-term retinal damage after resolved cotton wool spots. Ophthalmology 116: 2407– 2414.